ARROWHEAD PHARMACEUTICALS, INC. (ARWR): what the price assumes

In the published model solve dated 2026-Q2, anchored at $86.86, ARROWHEAD PHARMACEUTICALS, INC. (ARWR) is priced for today's economics sustained for ~19.2 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/ARWR

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 12.8% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.8 years.

Reconcile: at the x-ray's 9.3% required return this reads ~10.7 years; the models below use their own rates.

How unusual the bet is: elevated

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Asset, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.8%); the inversion above states its own rate.

Per-Model Detail (n=5)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Bullet Takeaways

• Arrowhead now has an approved drug of its own: REDEMPLO cleared the FDA on November 18, 2025 for familial chylomicronemia syndrome, priced at 45,000 dollars a year, with more than 400 prescriptions received or in process by early May.
• The revenue line is a partner schedule rather than a business: the Sarepta collaboration accounts for roughly 84% of it, and quarterly revenue fell to 73.7 million dollars in the March 2026 quarter from 542.7 million dollars a year earlier while the company lost 132.7 million dollars.
• The near-term swing factor is the Phase 3 readout in severe hypertriglyceridemia, with SHASTA-3 and SHASTA-4 topline data expected in the third quarter of 2026 and a supplemental filing targeted by year-end.

Bull Case

The advantage starts with a piece of biology that behaves unlike a drug. Arrowhead's medicines work by interfering with RNA, and its own annual report explains why that matters in one line: RNAi is a catalytic process, so each RNAi trigger can degrade mRNA hundreds of times. One molecule does its job repeatedly instead of once, which is why these treatments can be dosed a few times a year rather than daily. Around that biology sits the delivery system, which the company describes as offering simplified manufacturing and reduced costs; multiple routes of administration. Getting the molecule into the right cell is the hard part of this field, and it is where the durable advantage lives.

The most convincing evidence that the platform is worth something is that other companies keep paying for pieces of it. Sarepta paid a 500 million dollar upfront on February 14, 2025 under the collaboration agreement, alongside an equity investment, and Arrowhead earned a further 200 million dollar milestone in November 2025 when a Phase 1/2 study of ARO-DM1 hit its second development milestone. Sanofi holds a license covering plozasiran in China, and GSK is a third counterparty. Partners with their own scientists chose to rent this technology rather than build it, which is a harder-edged assessment than any analyst's.

Then the company proved it does not need a partner at all. REDEMPLO was approved by the FDA on November 18, 2025 and launched by Arrowhead itself, priced at 45,000 dollars a year, with European marketing authorization following in June 2026 and Canadian clearance behind it. By early May more than 400 prescriptions had been received or were in process, roughly 180 patients had received at least one shipment, and about 85% of them had never been treated with a drug in this class. Small numbers, but they answer the question a platform company eventually has to answer: can it run a commercial launch.

The wider prize is the same molecule in a much larger population. Plozasiran is in Phase 3 for severe hypertriglyceridemia, with SHASTA-3 and SHASTA-4 topline results expected in the third quarter of 2026 and a supplemental application targeted by the end of the year. Behind it sit programs aimed at obesity and complement-mediated disease. The pipeline is broad in a way that matters for a platform: several shots on goal that share manufacturing, chemistry and regulatory experience, so a success in one lowers the cost of the next.

Crucially, the balance sheet pays for all of it. Cash, equivalents and investments stood at 1.784 billion dollars at March 31, 2026 against quarterly research spending of 173.3 million dollars and general costs of 41.7 million dollars. That funds the current pace for roughly two years before counting a single additional partner payment, and the company has said the Sarepta transaction carries its runway into 2028. A clinical-stage company that does not have to raise money into a bad market gets to make scientific decisions rather than financing ones.

None of the standard valuation methods reach this price, and the bull case does not pretend otherwise. Discounted cash flows and book-value screens are built for businesses whose future looks like their past, and a pipeline of binary outcomes is not that. What the balance sheet, the partners and the first approval establish is that the option set is real and funded. The price is a claim about how many of those options come good.

Bear Case

Biotech has its own version of peak earnings, and this is what it looks like. Revenue in the quarter ended March 31, 2026 was 73.7 million dollars against 542.7 million dollars in the same quarter a year earlier, and the company lost 132.7 million dollars in the three months. Nothing broke between those two quarters. The earlier one simply contained a partner's cheque and the later one did not. Any profit figure drawn from the trailing period is measuring the timing of collaboration accounting rather than the earning power of a business, and every multiple built on it inherits that flaw.

The concentration underneath is severe. The Sarepta collaboration supplies roughly 84% of revenue and the Sanofi license most of the rest, so the top line depends on the clinical progress and the balance sheet of a small number of counterparties. Arrowhead's own annual report is candid about how reliable that makes the schedule: milestone payments are recognized only when events occur, and achievement of the milestone events are highly susceptible to factors outside of the entity's influence and therefore there is a possibility that the milestone event will not be achieved. A customer that can decide to slow a trial is a customer that can decide when you get paid.

The commercial base that would replace those payments is, for now, very small. Roughly 180 patients had received a shipment of REDEMPLO by early May, at about 30 new prescriptions a week and 45,000 dollars a year each. Familial chylomicronemia syndrome is an ultra-rare disease, and the filing does not soften the point: The potentially addressable patient population for our products may be limited or may not be amenable to treatment with our products. The larger hypertriglyceridemia population is where a commercial business would come from, and that indication is neither approved nor read out.

Set the price against any of that and the gap is wide. The market values the enterprise at something like 110 times trailing operating profit, and the arithmetic that reconciles that to today's economics requires them to compound at the fastest rate the business could self-fund for roughly two and a half decades. That solve carries low reliability, and it should: it is a signal that the price sits outside what this kind of arithmetic can describe, not a forecast of anything. What survives the caveats is the comparison, and the comparison is stark. The multiple sits at the very top of its peer distribution, well beyond the upper quartile, and among companies that have reached such levels only about 14% sustained them for a decade.

Meanwhile the ownership keeps thinning. The share count has grown about 7.2% a year over the last four years, so a holder from four years ago owns a materially smaller slice of the same pipeline. Borrowings run around 682 million dollars on a funded-debt basis, closer to 790 million once lease obligations are included, and interest costs absorb most of the trailing operating profit. The company also holds roughly 127 million dollars of equity stakes outside the operating business, which is about 1% of its market value: a real floor, and nowhere near a cushion.

The last uncomfortable fact is that renting the platform out does not lock anyone in. As the annual report puts it, Our commercialization or collaborative arrangements do not necessarily restrict our commercialization or collaborative partners from competing with us or restrict their ability to market or sell competitive products. The science may be excellent and the partners may be genuine. Neither guarantees that the value created stays with this shareholder register.

Valuation

Start with what this price is not built out of. Every family of standard method, asset-based, peer-multiple and forward-growth alike, lands below where the stock trades. For a clinical-stage company that result is close to inevitable rather than damning: book value measures laboratory equipment and cash, peer multiples measure a revenue line that arrives in irregular lumps, and cash-flow models cannot price a set of binary regulatory outcomes. The useful reading is not that the methods disagree with each other but that they agree, and that the price is being set by something none of them capture.

The arithmetic that does reach today's level is demanding to the point of abstraction. The enterprise is valued at roughly 110 times trailing operating profit, and holding today's economics with profit compounding at the fastest rate the business could finance internally, that price corresponds to something like two and a half decades of persistence. The band behind that calculation is low-reliability and should be treated as indicative rather than measured. What is not soft is the peer comparison: the multiple sits at the very top of its cohort, beyond the upper quartile, and of the companies that have reached comparable levels only about 14% held them for a decade.

Part of the reason the multiple looks the way it does is the denominator. Trailing operating profit here is positive because of collaboration payments, not product sales, and the shape of that revenue is visible in a single comparison: 73.7 million dollars in the March 2026 quarter against 542.7 million dollars in the same quarter a year before. A multiple calculated on the peak of that pattern flatters the stock; one calculated on the trough would condemn it. Neither is the business.

Revenue scale offers a cleaner comparison than multiples do. Arrowhead's trailing revenue sits in the same neighbourhood as several mid-cap developers in its cohort: AXSM at 708.2 million dollars growing 63.9%, TGTX at 700.3 million dollars, FOLD at 634.2 million dollars growing 20.0%, BBIO at 580.0 million dollars. What separates Arrowhead from most of them is where the revenue comes from. Theirs is largely product sales to patients; Arrowhead's is largely payments from partners, and the market is valuing the pipeline behind those payments rather than the payments themselves.

The balance sheet is what makes the wait affordable. Cash and investments totalled 1.784 billion dollars at March 31, 2026 against quarterly research spending of 173.3 million dollars, with borrowings near 682 million dollars on a funded-debt basis and closer to 790 million once leases are counted. The company is burning cash and diluting at roughly 7.2% a year, so the runway is real but not free. What the price is underwriting, in the end, is the conversion rate from a funded pipeline into approved drugs, and the next reading on that conversion arrives with the Phase 3 data due this quarter.

Catalysts

The event that matters most is close. Topline results from the SHASTA-3 and SHASTA-4 Phase 3 studies of plozasiran in severe hypertriglyceridemia are expected in the third quarter of 2026, with a supplemental new drug application targeted by the end of the year. The distinction between the approved indication and this one is the distinction between an ultra-rare disease and a population large enough to support a commercial franchise, so the readout does more to the investment case than any financial disclosure this year will.

The launch already underway is the second thread. REDEMPLO was approved on November 18, 2025 and is being sold by Arrowhead itself at 45,000 dollars a year; by the early-May update more than 400 prescriptions had been received or were in process, about 180 patients had received a shipment, and weekly prescriptions were running near 30. European marketing authorization followed in June 2026 and Canadian clearance is expected to translate into availability later in the year. Prescription growth and the share of patients who stay on therapy are the two numbers worth tracking each quarter.

Partner payments supply the third. Arrowhead earned a 200 million dollar milestone from Sarepta in November 2025 on a Phase 1/2 study of ARO-DM1, and further milestones across the licensed programs are tied to development events rather than the calendar. Those payments are why the revenue line jumps around, and each one that lands moves the funding horizon out without the company selling a share.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• GKOS (GLAUKOS Corp)
• FY2025 10-K: …superiority supported by extensive data and innovative features that enhance patient benefit, product performance, and safety. The ophthalmic segment of the medical technology and pharmaceutical industries is dynamic and subject to significant change due to cost-of-care considerations, reimbursement levels,…
• FY2025 10-K: …safety, quality or efficacy, (ii) reflect a broader label indication, or (iii) are available at lower prices. Our competitors include large publicly traded companies or divisions thereof and have more resources, greater name recognition, longer operating histories, more established relationships with healthcare…
• FOLD (AMICUS THERAPEUTICS, INC.)
• FY2025 10-K: …profits from operations. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including: -31- Table of Contents • the efficacy and potential advantages compared to competitive or alternative treatments, including generics and gene therapies; •…
• FY2025 10-K: …including commercial enterprises, academic institutions, government agencies, and private and public research institutions. Any product candidates that we successfully develop and commercialize will compete with both existing and new therapies that may become available in the future. Many of our competitors may have…
• BBIO (BridgeBio Pharma, Inc.)
• FY2025 10-K: …and timely manner to government programs. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws. 40 Table of Contents The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform,…
• FY2025 10-K: …not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary from our estimates, we will adjust these estimates prospectively in the period such change in estimate becomes known, which could affect net product revenue and earnings in the…
• MIRM (MIRM)
• FY2025 10-K: , generic pharmaceutical companies and universities and other research institutions who are active in rare disease. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and…
• FY2025 10-K: …to brelovitug, a late-stage, fully human monoclonal antibody for chronic hepatitis delta virus (HDV), a rare and severe liver disease. The Company views its operations and manages its business as one operating segment. The Company determined its operating segment on the same basis that it uses to evaluate its…
• VCYT (VERACYTE, INC.)
• FY2025 10-K: …In general, we also face competition from commercial laboratories, such as Laboratory Corporation of America Holdings, Quest Diagnostics, and Sonic Healthcare USA, with strong infrastructure to support the commercialization of diagnostic services. We also face potential competition from companies such as Thermo…
• FY2025 10-K: …accurately and plan production capacities accordingly. However, our sales depend on physician's ordering patterns, reimbursement, or customers' budgets that may be subject to significant and unexpected variation, including seasonality. Any decrease in spending or change in test ordering patterns by physicians or…
• TGTX (TGTX)
• FY2025 10-K: …We operate in a highly competitive segment of the biotechnology and biopharmaceutical market. We face competition from numerous sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies, and private and public research institutions. Many of our competitors…
• FY2025 10-K: …values and credit spreads that were boosted by extraordinary monetary stimulus. A severe or prolonged economic downturn could result in a variety of risks to our business, including, weakened demand for our drug candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak…
• HCM (HUTCHMED (China) Ltd)
• FY2025 20-F: …may put us at a competitive disadvantage relative to companies with more extensive product lines. In such case, our business, results of operations, financial condition and prospects will be materially and adversely affected. We face substantial competition in selling our approved, internally developed drugs and the…
• FY2025 20-F: …Company (US$ ' 000) 456,909 ​ 37,729 ​ 100,780 Diluted earnings per share attributable to the Company (US$ per share) 0.52 ​ 0.04 ​ 0.12 ​ ​ F- 47 Table of Contents 28. Segment Reporting The Group's operating segments are Oncology/Immunology and Other Ventures. Oncology/Immunology focuses on discovering, developing,…
• AXSM (AXSOME THERAPEUTICS, INC.)
• FY2025 10-K: …and is not material to the Company's consolidated financial statements. Segment Information Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision maker or decision-making group in deciding how to allocate…
• FY2025 10-K: …competition with respect to our current products and product candidates and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. There are…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.